Details for Patent: 9,314,439

Which drugs does patent 9,314,439 protect, and when does it expire?

Patent 9,314,439 protects SOHONOS and is included in one NDA.

This patent has thirty patent family members in nineteen countries.

Drugs Protected by US Patent 9,314,439

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ipsen	SOHONOS	palovarotene	CAPSULE;ORAL	215559-001	Aug 16, 2023		RX	Yes	No	9,314,439					REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA
Ipsen	SOHONOS	palovarotene	CAPSULE;ORAL	215559-002	Aug 16, 2023		RX	Yes	No	9,314,439					REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA
Ipsen	SOHONOS	palovarotene	CAPSULE;ORAL	215559-003	Aug 16, 2023		RX	Yes	No	9,314,439					REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA

International Family Members for US Patent 9,314,439

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2011296080
Brazil	112013004685
Canada	2809374